Reinvention: The Future of Cancer & Biomedical Innovation — and Careers
Join us for a fireside evening with Prof Toh Han Chong — Deputy CEO (Strategic Partnerships) of the National Cancer Centre Singapore and Professor at Duke-NUS. Few people have built across as many worlds: clinician-scientist, immunotherapy pioneer, lead PI of the global VANCE Phase III trial (the world’s largest T-cell therapy trial in solid tumours), and co-founder of the startup NeoTILa Biosciences.
He’s done what most of us are told to pick between — the lab, the clinic, and the cap table — and this is a rare chance to hear, candidly, how he did it and what he’d do differently.
We’ll get into the questions that don’t make it into journal papers:
How do you know when an idea is a company and not just a finding?
What separates exciting science from investable science?
How did a small nation engineer a world-class biomedical ecosystem — and where are the real openings right now for anyone looking toward Asia? and
If he were a grad student today, what would he learn that scientific training overlooks entirely?
Moderated by Rohit Nayak, Healthcare Leader at PwC.
Especially worth your evening if you’re a
Student or postdoc wondering whether you have to choose between science and building something
Founder eyeing Asian markets, manufacturing, capital — or figuring out how to make your science fundable
Executive or strategist in pharma, biotech, or health systems sizing up Asia for partnerships, trials, or expansion
Researcher exploring collaborations or trials in Asia
Investor mapping the region — or simply curious how life-science companies and ecosystems get built from the ground up
💼 PwC is hiring. If you’re interested in consulting, meet them over drinks.
Hosted by: PwC, Dr Cecelia Brown-Fleming (Stanford), Kenneth Sng (Founder, Bedside), Dr Jasmin Young (Co-founder, SingaporeConnect) and Ken Mun Wong (Enterprise Singapore).
🍷 Appetizers & networking. Seats are limited.